{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:55:38Z","timestamp":1791244538557,"version":"4.1.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.clgc.2015.12.011","type":"journal-article","created":{"date-parts":[[2015,12,17]],"date-time":"2015-12-17T19:00:24Z","timestamp":1450378824000},"page":"153-159","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Everolimus Versus Temsirolimus in Metastatic Renal Cell Carcinoma After Progression With Previous Systemic Therapies"],"prefix":"10.1016","volume":"14","author":[{"given":"Shiven B.","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David D.","family":"Stenehjem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivas K.","family":"Tantravahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archana M.","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JoAnne","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winston","family":"Vuong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumanta K.","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6574-8499","authenticated-orcid":false,"given":"Neeraj","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2015.12.011_bib1","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2015.12.011_bib2","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2015.12.011_bib3","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2015.12.011_bib4","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1586\/14737140.2013.833684","article-title":"The clinical potential of temsirolimus in second or later lines of treatment for metastatic renal cell carcinoma","volume":"13","author":"Stenner-Liewen","year":"2013","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.clgc.2015.12.011_bib5","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/annonc\/mdq320","article-title":"Temsirolimus in VEGF-refractory metastatic renal cell carcinoma","volume":"22","author":"Mackenzie","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2015.12.011_bib6","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00345-011-0676-1","article-title":"Sequential mTOR inhibitor treatment with temsirolimus in metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitors","volume":"31","author":"Weikert","year":"2013","journal-title":"World J Urol"},{"key":"10.1016\/j.clgc.2015.12.011_bib7","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.ctrv.2012.12.006","article-title":"A\u00a0contemporary update on rates and management of toxicities of targeted therapies for metastatic renal cell carcinoma","volume":"39","author":"Alasker","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clgc.2015.12.011_bib8","first-page":"275","article-title":"Review of US comparative economic evidence for treatment of metastatic renal cell carcinoma after failure of first-line VEGF inhibitor therapy","volume":"6","author":"Wong","year":"2013","journal-title":"Am Health Drug Benefits"},{"key":"10.1016\/j.clgc.2015.12.011_bib9","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.clgc.2012.09.008","article-title":"Everolimus vs. temsirolimus for advanced renal cell carcinoma: use and use of resources in the US Oncology Network","volume":"11","author":"Vogelzang","year":"2013","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2015.12.011_bib10","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.clgc.2012.04.006","article-title":"Second-line treatment outcomes after first-line sunitinib therapy in metastatic renal cell carcinoma","volume":"10","author":"Chen","year":"2012","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2015.12.011_bib11","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1185\/03007995.2014.949645","article-title":"Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: synthesis of findings from two multi-practice chart reviews in the United States","volume":"30","author":"Signorovitch","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clgc.2015.12.011_bib12","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1185\/03007995.2013.871243","article-title":"Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: a US medical record review","volume":"30","author":"Wong","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clgc.2015.12.011_bib13","doi-asserted-by":"crossref","first-page":"E121","DOI":"10.5489\/cuaj.1604","article-title":"Clinical outcomes in patients with metastatic renal cell carcinoma receiving everolimus or temsirolimus after sunitinib","volume":"8","author":"Iacovelli","year":"2014","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.clgc.2015.12.011_bib14","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.clgc.2014.07.006","article-title":"Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma: a systematic review and meta-analysis of literature data","volume":"13","author":"Iacovelli","year":"2015","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2015.12.011_bib15","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/j.clgc.2013.12.003","article-title":"A\u00a0population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma","volume":"12","author":"Alimohamed","year":"2014","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2015.12.011_bib16","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1200\/JCO.2004.08.185","article-title":"Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma","volume":"22","author":"Atkins","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2015.12.011_bib17","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1200\/JCO.2007.14.0988","article-title":"Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors","volume":"26","author":"O'Donnell","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2015.12.011_bib18","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1067\/mcp.2001.112969","article-title":"Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine","volume":"69","author":"Kovarik","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clgc.2015.12.011_bib19","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1634\/theoncologist.2010-0196","article-title":"Inhibitors of mTOR","volume":"15","author":"Kl\u00fcmpen","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.clgc.2015.12.011_bib20","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1200\/JCO.2013.50.3961","article-title":"Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma","volume":"32","author":"Hutson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl 15","key":"10.1016\/j.clgc.2015.12.011_bib21","article-title":"Third-line therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC)","volume":"33","author":"Heng","year":"2015","journal-title":"ASCO Annual Meeting Proceedings"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767315003419?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767315003419?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:25:48Z","timestamp":1761564348000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767315003419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S1558767315003419"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2015.12.011","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Everolimus Versus Temsirolimus in Metastatic Renal Cell Carcinoma After Progression With Previous Systemic Therapies","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2015.12.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}